There are 4 drugs targeting PLA2G4A included in the CMap collection, and all 4 significantly reverse lung cancer gene changes in our analyses: flunisolide, fluocinonide, fluorometholone, and medrysone. Here, PLA2G4A is linked to lung cancer.